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Abstract
DAP12 is an ITAM-bearing transmembrane adaptor originally identified on the surface of Natural Killer cells. A broad
expression among other immune cells was later found in myeloid and lymphoid cells. However, data on DAP12 expression
pattern rely only on immunoblot and microarray analysis. Here, we describe the generation and the characterization of an
anti-DAP12 monoclonal antibody. Using this novel reagent, we show that DAP12 expression is restricted to innate immune
cells in basal condition. Since a decreased expression of DAP12 has been suggested in NK cells of systemic lupus
erythematosus patients, we have further investigated the NK cell receptor repertoire and leukocyte expression of DAP12 in
these patients and no major changes were detectable when compared to controls.
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Introduction
DAP12 (DNAX Activating Protein of 12 kDa) is a transmem-
brane adaptor initially identified in Natural Killer cells [1,2,3].
This molecule is also named KARAP (Killer cell Activating
Receptor-Associated Protein) or TYROBP (TYROsine kinase
Binding Protein). The presence of a YxxL–(x)7–YxxL sequence in
its intracellular tail defines it as a canonical ITAM-bearing
molecule. This motif has been described in many adaptors that are
crucial to expression and function of various activating immunor-
eceptors. After receptor ligation, the two tyrosine of the ITAM are
phosphorylated and serve as high affinity docking site for the
recruitment of the tandem SH2-containing protein tyrosine
kinases ZAP-70 and p72
syk, which in turn are activated and
phosphorylate many critical downstream signalling components.
Along this line, DAP12 participates in cytotoxicity and cytokine
production of NK cells [4,5].
Although initially described in NK cells, DAP12 expression has
been reported in various hematopoietic cells such as osteoclasts,
neutrophils, macrophages and dendritic cells [4]. Interestingly,
some T and B cell subsets also express DAP12 under inflammatory
conditions. In humans, CD4
+ CD28
2 T cells that express both
DAP12 and activating KIR (Killer-cell Ig-like Receptor) have been
described in patients suffering from chronic inflammatory diseases
[6,7]. In mice, LPS-stimulated B cells express DAP12 in
association with the immunoglobulin-like receptor II (MAIR-II)
[8,9]. Surprisingly, although the expression of ITAM-bearing
adaptors is crucial to the expression of various activating
immunoreceptors, some DAP12-negative T cells can express
activating KIR [10]. These data suggest that an as yet unidentified
adaptor molecule could associate with and stabilize cell surface
expression of activating KIR in T cells that do not express DAP12.
The function of DAP12 is more complex than originally
thought, as it can downregulate TLR-dependent responses in
macrophages as well as CD16-dependent responses in NK cells
[11,12]. Similarly, DAP12 down-modulates the cytokine produc-
tion by plasmacytoid dendritic cell (pDC) in vivo during murine
cytomegalovirus infection [13]. Unraveling molecular mechanisms
by which DAP12 can induce either activating or inhibiting signals
will provide major informations on the fine tuning of immune
responses.
Mutations in the human DAP12 gene induce a rare pathology
named polycystic lipomembraneous osteodysplasia with sclerosing
encephalopathy (PLOSL), also known as Nasu-Hakola disease
[14]. These patients do not present any obvious immunological
defects, but are affected by severe bone and brain alterations. At
early adulthood, first symptoms are pain and frequent fractures in
the bone. The bone resorption is controlled by osteoclasts that
derived from the monocytic lineage. In vitro the osteoclast
differenciation is dramatically affected both in DAP12-deficient
PLOSL patients and DAP12-deficient mice [15,16,17,18]. Later
PLOSL patients develop frontal lobe syndrome with a diffuse
brain inflammation and dementia.
The combination of neurological, bone and inflammatory
disorders which are associated with an alteration of DAP12
expression prompted us to generate a reagent compatible with
diverse immunodetection procedures. Here, we describe the
production and the characterization of a rat anti-human DAP12
monoclonal antibody. This antibody was used to determine
DAP12 expression pattern in human peripheral blood leukocytes
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combination with the NK cell receptor repertoire, in systemic
lupus erythematosus patients. Indeed, a reduced amount of NK
cells, associated with altered functions and a down-modulation of
DAP12 have been reported in this disease [19,20,21,22].
Results
Characterization of a novel rat anti-human DAP12
monoclonal antibody
The rat H10E12F4 IgG1 (thereafter referred as to F4 mAb) was
selected by its ability to bind specifically the DAP12 protein in an
ELISA test (data not shown). To further analyze its specificity, a
flow cytometry analysis of DAP12 expression was performed on
RBL cells expressing DAP12 (RBL-CD158j/DAP12) or not (RBL-
CD158j). As shown in figure 1, a positive staining by F4 antibody
was only detectable in permeabilized DAP12-positive RBL cells.
This result was confirmed using lentiviral transduction of human
DAP12 cDNA both in DAP12-negative CD8+ T cells and
DAP12-negative HEK cells (data not shown). This F4 mAb can
be also used to detect DAP12 in Western-Blot as well as in
immunohistochemistry assays (data not shown).
DAP-12 expression pattern in healthy and systemic lupus
erythematosus patients
Since the original description of DAP12 expression in NK cells,
a broader expression among other immune cells has also been
found in mouse and human, both in myeloid and lymphoid cells,
and many DAP12-associated activating membrane receptors have
been described. However, data about DAP12 expression in
humans relies on Western blot and microarrays studies. Thus,
the F4 mAb was used to provide additional data about the
expression of the polypeptide DAP12 in leukocytes from healthy
individuals. Whole blood sample from healthy donors were stained
in a first step by lymphocytes surface markers (CD4, CD8, CD19,
CD56, CD3, Va24,V b12, TCRcd). Then the cells were
permeabilized and stained by Alexa 647-conjugated F4 antibody.
DAP12 expression was barely detected in CD8
+ T lymphocytes,
CD4
+ T lymphocytes, CD19
+ B lymphocytes, cd
+ T lymphocytes
and Va24 NKT lymphocytes (Figure 2A). By contrast DAP12
expression was detected in the NK cell population with no
difference between CD56
bright and CD56
dim sub-populations
(Figure 2B).
The expression of DAP12 in other cells involved in innate
immunity and expressing several DAP12-associated receptors was
then evaluated (Figure 2C). Among these cells, monocytes express
TREM-1, SIRP-b, MDL-1 and IREM-2 receptors. Thus, F4
staining on distinct monocyte sub-populations that co-expressed
CD14 and CD33 molecules was analysed. A strong staining of
both CD16
+ and CD16
2 monocyte subsets was observed.
Dendritic cells (DC) also express several DAP12-associated
receptors, such as PIRL-b, SIRP-b, IREM-2 and TREM-2. DC
were defined as ILT-3
+/CD14
+/CD16
2 cells. DAP12 was highly
expressed both in plasmocytoid (CD33
low) and conventional
(CD33
high) DC sub-populations. Finally neutrophils are DAP12-
positive cells.
Since it was previously described a lower NK cell number in
SLE patients, we have quantified and compared the leukocyte
subsets from SLE patients and control individuals. NK absolute
counts and percentage of total lymphocyte were first compared to
our large control group of 92 healthy donors. The mean of NK
absolute counts was significantly decreased in SLE patients
compared to controls (106/ml615 versus 259/ml614, p,0.0001)
(Table 1). The NK cell percentage of total lymphocytes was also
significantly decreased in SLE patients compared to this control
group (7.81%61.19 versus 12.01%60.59, p=0.011). However,
when compared to the control group of 10 healthy donors, used
for the NK cell phenotype analysis, there was only a trend toward
a decrease in NK cell percentage in SLE patients that did not
reach significance (7.81%61.19 in SLE patients compared to
11.59%62.25 in controls, p=0.12). There is no significant change
in the proportion of CD56
dim and CD56
bright subsets between the
two groups (Table 2).
The quantification of other leukocytes subsets has shown that
the percentage of circulating DC was significantly decreased in
SLE patients compared to controls, considering both plasmacytoid
DC (0.1660.08 versus 0.2460.074, p=0.04) or conventional DC
(0.1960.09 versus 0.3260.09, p=0.003) (Table 2). On the
contrary, the percentages of neutrophils or monocytes were not
different in SLE patients compared to controls.
It was previously described by western-blot analysis a down-
regulation of DAP12 expression in NK cells from SLE patients. In
addition, DAP12 is also expressed by other leukocytes such as DC
which have been clearly involved in lupus physiopathogeny. This
prompted us to extend on leukocyte subsets the analysis of DAP12
expression in SLE. The number of DAP12-positive NK cells was
slightly decreased compared to our control group of healthy
subject (96.67%62.02 versus 97.66%63.23, p=0.02) (data not
shown). Conversely, there is no significant modulation of the MFI
for DAP12 expression by NK cells (Table 2). The expression of
DAP12 in DCs, monocytes and neutrophils are similar in the two
groups (Table 2).
NK cell receptor repertoire of systemic lupus
erythematosus patients
It has been shown that NK cell functions are altered in SLE
patients. A modulation in the expression of activatory and
inhibitory NK cell receptors, implicated in the tuning of NK cell
activation, could be associated with a decrease in NK cell
functions. Moreover DAP12 is crucial to signalling of many NK
cell activatory receptors.
Phenotypical characterization of NK cells was performed by
analyzing the expression of many receptors such as NKp46,
NKp30, NKp44, NKG2D, CD244, CD2, CD16, CD69, CD159a,
CD158a/h, CD158b1/b2/j, CD158e1/e2, CD158i and NKG2A.
The results show only minor phenotypical changes between SLE
patients and controls (figure 3). There is a significant decrease of
CD16 MFI (p=0.03) and of the proportion of CD244
+ NK cells
(p=0.002) associated with an increase of the CD158 b1/b2/j MFI
(p=0.02) in the SLE group. No difference for the expressions of
NKp46, NKp30, NKp44, CD2, CD69, NKG2A, CD158a/h,
CD158e1/e2 and CD158i was observed in SLE patients
compared to controls.
Discussion
We have generated a rat monoclonal antibody (F4) directed
against human DAP12 for which the specificity was validated in
three independents transfection models. This anti-human DAP12
monoclonal antibody represents a powerful tool to investigate
DAP12 expression in patients.
This report is the first description of basal expression of DAP12
protein in distinct human leukocyte subpopulations from healthy
individuals. These results validate the restricted expression of
DAP12 in cells involved in innate immunity (Figure 2D) and are
consistent with public databases of transcript pattern of DAP12
(http://symatlas.gnf.org) [23].
DAP12 Expression in SLE
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detected. This F4 staining was abrogated upon preincubation of F4
antibody with the GST-DAP12 immunogen and was unchanged
after preincubation of F4 antibody with an irrelevant GST protein,
suggesting a specific but weak binding (data not shown). Then, we
hypothesized that alternative transcripts of DAP12, that are not
detected by classical RT-PCR, are recognized by the F4 mAb. To
address this issue, specific primers of DAP12 were designed to
amplify from exon 1 to 3, 1 to 4, 1 to 5 and 3 to 5. Using these
primers, no transcripts were detected in cells known as DAP12
negative (data not shown). The F4 mAb could also cross-react with
anasyetunknown protein.SinceF4mAbdoes not recognize mouse
DAP12, we aligned proteic sequence of human and mouse
intracellular domains of DAP12 and we identified species specific
amino acid sequences. Most of gaps were found in the aminoterm-
inal part of the intracellular domain. This region was blasted using
NCBI server, but no significant hit was found. At this time, we are
not able to explain the dull staining observed in some DAP12-
negative cells. We cannot formally exclude the existence of another
adaptor that could be recognized by F4 mAb with a weaker affinity
compared to DAP12.
To conclude, the rat IgG1monoclonal antibody F4 allows an
efficient detection of DAP12 expression in monocytes, dendritic
cells, neutrophils and natural killer cells. Indeed, in some
inflammatory conditions, it would be a useful reagent to monitor
DAP12 expression in B and T cell populations.
The circulating NK cells from our cohort of SLE patients
presented only mild phenotypical changes when compared to NK
cells from controls. An increase of the CD56
bright subset has been
reported in SLE patients [24]. This NK cell subset is of interest in
SLE because it represents the main NK cells found in secondary
lymphoid tissues and inflamed tissues. We also report a weak
increase of the CD56
bright subset, however this change is not
significant due to the great interindividual variability. This
discrepancy could be explained by the low activity index of SLE
in our cohort.
Figure 1. F4 MAb recognizes DAP12 antigen in transfected RBL cells. Stable transfectants of the rat basophilic leukemia cell line (RBL) have
been described earlier [31]. In brief, RBL-CD158j and RBL-CD158j/DAP12 have been obtained by transfection with human cDNAs encoding CD158j
alone or both CD158j and human DAP12, respectively. RBL cells were fixed by incubation with 2% paraformaldehyde at room temperature. Then the
cells were permeabilized by Permwash treatment (Beckton Dickinson) before staining with 50 mg/ml irrelevant or F4 antibody on ice for 30 min. After
three washes in cold PBS, the cells were incubated 1:100 FITC-conjugated goat anti-rat immunoglobulins.
doi:10.1371/journal.pone.0006264.g001
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class I NK cell receptors. Moreover susceptibility to some
autoimmune and inflammatory diseases have been genetically
linked to these receptors [25]. In our study, the levels of NKG2A
(CD159a), CD158a/h, CD158e1/e2, CD158i expression by NK
cells from SLE patients were in the normal range with the
exception of the CD158b1/b2/j receptors for which an increased
MFI is observed. However, the percentage of CD158b1/b2/j
+
NK cells was similar in SLE patients and controls.
Along the same line, the abnormal expression of the Natural
Cytotoxicity Receptors (NCR) reported in primary Sjo ¨gren
syndrome was proposed to explain the decrease of NK cell
cytotoxity in this autoimmune disease [26]. By contrast to these
results, the expression of NKp44 (data not shown), NKp46 and
NKp30 were not significantly different from controls. We also
investigated the expression of CD244, CD16 and CD2. Although
the percentage of NK cells expressing CD244 was slightly
decreased, there is no difference in the MFI. Moreover, while
the MFI of the CD16 staining was also slightly decreased, there is
no modification of the percentage of CD16
+ NK cells. At last, the
expression of CD2 is identical in the two groups. Thus, altogether
these results show the absence of a major modulation of the
expression of NK cell receptors in our cohort of SLE patients.
Since the DAP12 adaptor molecule is used by many receptors to
transduce activating signals, its expression was analysed in distinct
leukocyte subpopulations by flow cytometry using the F4 mAb. No
Figure 2. Analysis of DAP12 expression on leukocytes. Whole-blood samples from 10 healthy donors were collected and stained in a first step
with several surface markers. The following mouse mAb from Immunotech-Beckman-Coulter were used: FITC-CD19 (J4.119), ECD-CD3 (UCHT1), FITC-
CD16 (3G8), FITC-CD4 (13B8.2), FITC-CD8 (B9.11), FITC-CD33 (D3HL60.251), PECy7-CD14 (RMO52), FITC-TCR Va24 (C15), PE-TCR pancd (IMMU510),
PECy7-CD56 (N901), PE-ILT3 ou PE-CD85k (ZM3.8). The blood was then treated with the IntraPrepTM permeabilization reagent and stained with DAP-
12-Alexa 647-conjugated antibody (H10E12F4) (Immunotech-Beckman-Coulter). A. After gating lymphocyte population using SSC/FSC plot, T and B
lymphocyte sub-populations were defined as follows: B lymphocytes are CD19
+ cells, auxiliary T lymphocytes are CD3
+/CD4
+ cells, cytotoxic T
lymphocytes are CD3
+/CD8
+ cells, cdT lymphocytes are TCRcd-positive cells and NKT lymphocytes are CD56
+/CD3
+/Va24
+. B. After gating lymphocyte
population using SSC/FSC plot, total NK cells are defined as CD3
2/CD56
+ cells and analyzed according to their level of CD56 expression. C.
Monocytes were defined on the size/CD33
+ gate as CD16
+ or CD14
+. Expression of DAP12 was analysed in these double-positive cells that can
express or not the CD16 molecule. Dendritic cells were defined as ILT3
+/CD14
dim to negCD16
neg within the lymphocyte and monocyte gate and further
characterized as plasmacytoid CD33
low DC and conventional CD33
high DC. Neutrophils were defined on the size/CD16
+ gate. D. Schematic
representation of the expression of DAP12 by leukocyte subsets from healthy individuals.
doi:10.1371/journal.pone.0006264.g002
Table 1. Number of NK cells in SLE and control patients.
Controls (n=92) SLE (n=13)
Absolute number 259614/ml1 0 6 615/ml
% 12.0160.59 7.8164.30
Absolute numbers and percentage of NK cells among total lymphocytes are
indicated for the control group (n=92) and the SLE group of 13 patients.
doi:10.1371/journal.pone.0006264.t001
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% of DAP12-positive cells MFI of DAP12 staining
Controls (n=10) SLE (n=13) Controls (n=10) SLE (n=13)
NK 11.5967.13 7.8164.3 2.9160.64 3.6761.05
CD56
bright 3.7766.47 11.53610.63 6.3763.76 6.6863.36
CD56
dim 89.56613.38 87.30611.09 2.4760.48 2.8660.78
DC Plasmacytoid DC 0.2460.07 0.1660.08 4.0660.74 3.6261.46
Conventional DC 0.3260.09 0.1960.09 4.1460.77 4.2960.64
Monocytes CD33
+ CD14
+ 6.9261.83 7.2162.07 7.2261.17 6.7260.99
CD33
+ CD16
+ 0.8760.36 1.1060.96 6.0661.26 6.6261.32
Neutrophils 47.7968.95 55.57610.86 4.8661.40 4.8060.93
Both percentage of NK cells among total lymphocytes and percentage of the CD56
bright and CD56
dim subsets among NK cells are indicated. The percentage of dendritic
cells, monocytes and neutrophils among the leukocytes are given. Statistically significant values are shown in bold.
doi:10.1371/journal.pone.0006264.t002
Figure 3. NK cell receptors percentage and MFI in SLE patients and controls. Cell surface expression of indicated molecules on NK cells
within peripheral blood lymphocytes from controls (squares) and SLE patients (triangles) are given as percentage of total NK cells and MFI. Horizontal
bars indicate median values. The p value is mentioned above a given NK cell subset when a statistically significant difference is observed between the
two groups.
doi:10.1371/journal.pone.0006264.g003
DAP12 Expression in SLE
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subpopulations from SLE patients compared to controls. Only few
NK cells are DAP12-negative in SLE patients and the percentage
of expression are very close to controls. Contrary to our results,
Toyabe et al. have reported a decreased expression of DAP12 in NK
cells from SLE patients by using western blot analysis with a rabbit
anti-human DAP12 antibody [21]. Similarly to our study, their
patients were mostly untreated and they displayed a relatively low
SLEDAI score, suggesting that this discrepancy is not related to
patient characteristics but rather to the methods used for DAP12
detection in NK cells.
To conclude, our results confirm that the basal expression of
DAP12 is restricted to cells of innate immunity in healthy
individuals. In addition, this study shows that the functional
deficiency of NK cell cytotoxicity in SLE patients is not related to
an abnormal expression of the NK cell receptors or DAP12
protein, as it has been previously shown with NCRs in acute
myelogenous leukaemia [27].
Materials and Methods
Generation and characterization of a novel mAb directed
against human DAP12
Hybridomas were generated by fusion of splenocytes from an
immunized rat with the Ag8-X63 plasmocytoma. Rats Lou
(Harlan) were immunized with a GST-DAP12 protein containing
the intracellular moiety of human DAP12 fused to the GST
protein. The coding sequence of the intracellular part of human
DAP12 was obtained by PCR using specific primers (59 primer,
59GGGATCCCGGCTGGTCCCT-39 and 39 primer, 59-
CGAATTCTGTCATGATTCGGGC-39) and cloned in BamHI
and EcoRI restriction sites of pGEX-4-T1 vector (GE Healthcare).
Bacteria transformation and fusion protein production and
purification were performed according to manufacturer’s instruc-
tions (GE Healthcare). Rats were subcutaneously immunized at 3-
weeks intervals with 100 mg of purified GST-DAP12 solution
emulsified in an equal volume of Freund’s adjuvant (complete for
the first injection and uncomplete for the following boosts). The
fusion protocol was previously described [28]. Briefly, splenocytes
from immunized rats were fused with Ag8-X63 plasmocytoma
cells. Ten days after the fusion, the presence of specific antibodies
in supernatants of hybridoma cultures was evaluated by ELISA.
Positive hybridomas were cloned twice by limiting dilution in 96-
well culture plates. Purification of the monoclonal antibody was
performed by protein G-sepharose affinity chromatography.
Patients
Patients enrolled in the study (n=13) were recruited from our
Department of Internal Medicine. They presented with SLE and
fulfilled the American Rheumatism Association 1982 revised
criteria, except 2 patients presenting with only 3 criteria and thus
considered as lupus-like syndrome. Characteristics of the patients
and ongoing treatments are summarized in Table 3. Disease
activity was assessed by a modified SLE disease activity index
(SLEDAI) score [29]. 10 healthy volunteers (controls) were
recruited from the CPCET (Centre de Pharmacologie Clinique
et d’Evaluations The ´rapeutiques). CPCET is an official facility
from our hospital where healthy volunteers are enrolled in studies
after written informed consent is obtained in accordance with
ethics and law. For NK cell absolute numbers and percentage of
total lymphocytes, additional statistical comparison was made with
values obtained in a previously reported large control cohort of
healthy subjects [30]. This study did not require the approvement
of an ethical committee as it was performed without any
supplemental blood prelevement. The analysis were performed
on blood samples used for routine analysis during the follow-up. A
patient written informed consent was obtained in accordance with
the French law.
MAb and Flow cytometry
The following mouse mAbs were used: ECD-CD3 (UCHT1),
FITC-CD16 (3G8), FITC-CD4 (13B8.2), FITC-CD8 (B9.11),
FITC-CD33 (D3HL60.251), PECy7-CD56 (N901), PE-ILT3 ou
PE-CD85k (ZM3.8), PE-NKG2D (ON72), PE-NKp30 (Z25), PE-
NKp44 (Z231), PE-NKp46 (Bab281), PE-CD159a/NKG2A
(Z199), PE-CD158a/h (EB6B), PE-CD158b1/b2/j (GL183), PE-
Table 3. Patients characteristics.
N Age Sex WBC Ly NK Treatment ANA titer Type dsDNA titer ACR
1 45 f 2340 790 79 MMF+P 800 SSA/SSB 216 7
2 27 m 9490 4600 170 H+P 800 Sm/RNP 2 5
3 27 m 5970 1740 158 H+P 800 RNP 31 5
4 26 f 4750 1540 92 H 400 SSA 6 3
5 34 f 6440 2080 62 H 600 - 2 4
6 28 f 6700 2180 218 H+P 600 SSA 4 6
7 40 f 3390 790 95 H+P 800 RNP/SSA 199 5
8 32 f 5890 1370 96 H+P 100 SSA 69 4
9 29 f 6790 710 35 H+P4 0 0 - 2 64
10 43 f 4580 1140 80 P 800 SSA/SSB 31 4
11 28 f 2990 1290 51 P 200 - 1 4
12 48 f 7790 1830 165 P 800 RNP 2 3
13 38 f 2370 840 79 none 800 SSA/SSB 2 4
Quantification of total White blood cells (WBC), total lymphocytes (Ly) and NK cells are indicated in cells per ml. Treatment for each patient is shown: MMF for
mycophenolate mofetil, H for hydroxychloroquine and P for prednisone (at time of analysis all patients received #10 mg/day of prednisone). Main biological
characteristics of autoantibodies are shown: antinuclear antibodies (ANA) titer, type of ANA and titer of anti-dsDNA autoantibodies (N,7). The number of ACR criterias
for each patient is indicated.
doi:10.1371/journal.pone.0006264.t003
DAP12 Expression in SLE
PLoS ONE | www.plosone.org 6 July 2009 | Volume 4 | Issue 7 | e6264CD158e1/e2 (Z27.3.7), PE-CD158i (FES172), PE-CD69
(TP1.55.3), PE-CD2 (39C1.5), PE-CD244 (C1.7) and DAP-12
Alexa 647 (H10E12F4), (all from Beckman Coulter). NK cells were
defined as the CD3
2CD56
+ cells within the lymphocyte size/
structuregate.DendriticcellsweredefinedasILT3
+/CD14
dim to neg
CD16
neg within the lymphocyte and monocyte gate and further
characterized as plasmacytoid DC CD33
low and conventional DC
CD33
high. Monocytes were defined on the size/CD33
+ gate as
CD16
+ or CD14
+. Neutrophils were defined on the size/CD16
+
gate.
Whole blood samples from donors were collected and stained in
a first step with several surface markers. The blood was then
treated with a permeabilization reagent (IntraPrep
TM permeabi-
lization reagent IM2388) and stained with DAP-12 Alexa-647
conjugated antibody. All samples were analyzed on a Cytomics
FC500 flow cytometer using CXP software (Beckman Coulter,
Miami, US).
Statistical analysis
Graphic representation and statistical analysis of NK cell
phenotype were obtained using Graphpad Prism software (San
Diego, CA). Comparison of distributions was performed using the
Mann-Whitney U-tests. Results were considered as significant with
ap ,0.05.
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